SOLENO THERAPEUTICS INC (SLNO) is a publicly traded company in the Unknown sector. Across all available filings, 38 corporate insiders have executed 456 transactions totaling $204.8M, demonstrating a bearish sentiment with -$64.2M in net insider flow. The most recent transaction on Jan 21, 2026 involved a transaction of 131,400 shares valued at $0.
No significant insider buying has been recorded for SLNO in the recent period.
No significant insider selling has been recorded for SLNO in the recent period.
Based on recent SEC filings, insider sentiment for SLNO is bearish with an Insider Alignment Score of 34/100 and a net flow of -$64.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at SOLENO THERAPEUTICS INC (SLNO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 38 insiders are actively trading SLNO stock, having executed 456 transactions in the past 90 days. The most active insider is Opportunity Fund Holdings, L.p. Vivo (Executive), who has made 4 transactions totaling $70.3M.
Get notified when executives and directors at SLNO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Anish Bhatnagar | Executive | Award | 131,400 | $N/A | $0 | |
| Jan 21, 2026 | Anish Bhatnagar | Executive | Award | 114,200 | $N/A | $0 | |
| Jan 21, 2026 | C. Hirano Patricia | SEE REMARKS | Award | 11,900 | $N/A | $0 | |
| Jan 21, 2026 | C. Hirano Patricia | SEE REMARKS | Award | 10,400 | $N/A | $0 | |
| Jan 21, 2026 | F. Huang Michael | Sr. VP of Clinical Development | Award | 11,900 | $N/A | $0 | |
| Jan 21, 2026 | F. Huang Michael | Sr. VP of Clinical Development | Award | 10,400 | $N/A | $0 | |
| Jan 21, 2026 | Joshi Manher | Chief Development Officer | Award | 4,700 | $N/A | $0 | |
| Jan 21, 2026 | Joshi Manher | Chief Development Officer | Award | 4,100 | $N/A | $0 | |
| Jan 21, 2026 | H. Mackaness James | CHIEF FINANCIAL OFFICER | Award | 32,800 | $N/A | $0 | C-Suite |
| Jan 21, 2026 | H. Mackaness James | CHIEF FINANCIAL OFFICER | Award | 28,600 | $N/A | $0 | C-Suite |
| Jan 21, 2026 | Manning Meredith | Chief Commercial Officer | Award | 32,800 | $N/A | $0 | |
| Jan 21, 2026 | Manning Meredith | Chief Commercial Officer | Award | 28,600 | $N/A | $0 | |
| Jan 21, 2026 | Norrett Kevin | Chief Business Officer | Award | 4,000 | $N/A | $0 | |
| Jan 21, 2026 | Norrett Kevin | Chief Business Officer | Award | 3,500 | $N/A | $0 | |
| Jan 21, 2026 | Yen Kristen | SEE REMARKS | Award | 11,900 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 203 | $134.5M | 58.4% |
Purchase(P) | 97 | $70.3M | 30.5% |
Exercise (Options)(X) | 3 | $18.9M | 8.2% |
Award(A) | 115 | $2.6M | 1.1% |
Other(J) | 8 | $2.2M | 1.0% |
Payment(F) | 17 | $959.2K | 0.4% |
Conversion(C) | 1 | $577.4K | 0.3% |
Exercise(M) | 9 | $139.7K | 0.1% |
Gift(G) | 3 | $0 | 0.0% |
Insider selling pressure at SOLENO THERAPEUTICS INC has increased, with 38 insiders executing 456 transactions across all time. Total sales of $134.5M significantly outpace purchases of $70.3M, resulting in a net outflow of $64.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.